Revolution Medicines is trading 4.53% down at $198.27 on October 6, 2026, with a reported 2.50% decline in the biotech sector providing the clearest available context. - The company announced today that it began treating patients in a Phase 3 pancreatic-cancer trial; available information does not link the news to the decline. - Major market indexes were higher, and no specific company catalyst explaining the drop is established.